Table 3 Primary treatments of patients in BCA and HER2+ BCA study cohorts
| Primary treatment | BCA cohort (n = 308) | HER2-amplified BCA cohort (n = 177) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Breast surgery | ||||
| Mastectomy (ablation) | 161 | 52.4 | 101 | 57.1 |
| Conservative surgery (resection) | 146 | 47.6 | 72 | 40.7 |
| No operation | 3 | 0.6 | ||
| Unknown | 1 | |||
| Post-operative radiotherapy | 198 | 65.3 | 110 | 62.1 |
| No | 105 | 34.7 | 67 | 37.9 |
| Unknown | 5 | |||
| Adjuvant endocrine therapy | 97 | 32.1 | 104 | 58.8 |
| No | 205 | 67.9 | 73 | 41.2 |
| Unknown | 6 | |||
| Adjuvant chemotherapy | 40 | 13.4 | 133 | 75.1 |
| No | 259 | 86.6 | 44 | 24.9 |
| Unknown | 9 | |||
| Adjuvant trastuzumab | 82 | 46.3 | ||
| No | 308 | 100.0 | 95 | 53.7 |